CoChat

AlphaFold accelerates artificial intelligence powered drug discovery: efficient discovery of a novel CDK20 small molecule inhibitor

Open access

The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.

Abstract

A novel CDK20 small molecule inhibitor discovered by artificial intelligence based on an AlphaFold-predicted structure demonstrates the first application of AlphaFold in hit identification for efficient drug discovery.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1039/d2sc05709c

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 The pipeline to combine AlphaFold with Insilico Medicine end-to-end, and AI-powered drug discovery platforms PandaOmics and Chemistry42 in the drug discovery for hepatocellular carcinoma from target selection and hit generation to hit identification. A novel therapeutic target was identified from a pool of dark targets that have AlphaFold-predicted but lack experimentally determined structures. Such a target represents a first-in-class novel target which is revealed for the first time to treat HCC.
Fig. 1 The pipeline to combine AlphaFold with Insilico Medicine end-to-end, and AI-powered drug discovery platforms PandaOmics and Chemistry42 in the drug discovery for hepatocellular carcinoma from target selection and hit generation to hit identification. A novel therapeutic target was identified from a pool of dark targets that have AlphaFold-predicted but lack experimentally determined structures. Such a target represents a first-in-class novel target which is revealed for the first time to treat HCC.CC BY · PubMed Central
Fig. 2 Reported CDK20 inhibitors from the literature and the novel inhibitor ISM042-2-048 discovered in this paper. The Tanimoto similarities of reported molecules to ISM042-2-048 are calculated from Morgan fingerprints using RDKit.1
Fig. 2 Reported CDK20 inhibitors from the literature and the novel inhibitor ISM042-2-048 discovered in this paper. The Tanimoto similarities of reported molecules to ISM042-2-048 are calculated from Morgan fingerprints using RDKit.1CC BY · PubMed Central
Fig. 3 Insilico Medicine generative procedures for CDK20 hits.
Fig. 3 Insilico Medicine generative procedures for CDK20 hits.CC BY · PubMed Central
Fig. 4 (A) The AlphaFold predicted structure of CDK20 (AF-Q8IZL9-F1-model_v1); (B) ATP pocket of CDK20 with a DFG-in (residue Phe146) conformation. Met84 is the hinge residue. P-loop is colored in green. Two acid centers Asp87 and Glu90 are located in the solvent-exposed region of the protein.
Fig. 4 (A) The AlphaFold predicted structure of CDK20 (AF-Q8IZL9-F1-model_v1); (B) ATP pocket of CDK20 with a DFG-in (residue Phe146) conformation. Met84 is the hinge residue. P-loop is colored in green. Two acid centers Asp87 and Glu90 are located in the solvent-exposed region of the protein.CC BY · PubMed Central
Fig. 5 Chemical structures for the selected 7 molecules from the first-round Chemistry42 generation for synthesis and testing in CDK20 binding assay.
Fig. 5 Chemical structures for the selected 7 molecules from the first-round Chemistry42 generation for synthesis and testing in CDK20 binding assay.CC BY · PubMed Central
Fig. 6 (A) Representative binding affinity curve of ISM042-2-001 in CDK20 kinase binding assay. Data points are presented as the mean of duplicate wells in one experiment. Similar results were obtained in three independent experiments and the KD is the mean ± SD of three independent experiments. (B) Predicted binding pose for ISM042-2-001 with CDK20.
Fig. 6 (A) Representative binding affinity curve of ISM042-2-001 in CDK20 kinase binding assay. Data points are presented as the mean of duplicate wells in one experiment. Similar results were obtained in three independent experiments and the KD is the mean ± SD of three independent experiments. (B) Predicted binding pose for ISM042-2-001 with CDK20.CC BY · PubMed Central
Fig. 7 Chemical structures for the second-round Chemistry42 generation for synthesis and testing in CDK20 binding and kinase activity assays. Biological data with a standard deviation are presented from three independent experiments.
Fig. 7 Chemical structures for the second-round Chemistry42 generation for synthesis and testing in CDK20 binding and kinase activity assays. Biological data with a standard deviation are presented from three independent experiments.CC BY · PubMed Central
Fig. 8 (A) Representative binding affinity curve for ISM042-2-048 in CDK20 kinase binding assay. Data points are presented as the mean of duplicate wells in one experiment. Similar results were obtained in three independent experiments and the KD is the mean ± SD of the three independent experiments. (B) Predicted binding pose for ISM042-2-048 in CDK20.
Fig. 8 (A) Representative binding affinity curve for ISM042-2-048 in CDK20 kinase binding assay. Data points are presented as the mean of duplicate wells in one experiment. Similar results were obtained in three independent experiments and the KD is the mean ± SD of the three independent experiments. (B) Predicted binding pose for ISM042-2-048 in CDK20.CC BY · PubMed Central
Fig. 9 (A) Representative dose–response curve for ISM042-2-048 in CDK20 kinase activity assay. Similar results were obtained in three independent experiments and the IC50 is the mean ± SD of the three independent experiments. (B) Cell viability curves for ISM042-2-048 in cell line Huh7 and counter screen cell line HEK293. Data points are presented as the mean of duplicate wells in one experiment. Similar results were obtained in three independent experiments.
Fig. 9 (A) Representative dose–response curve for ISM042-2-048 in CDK20 kinase activity assay. Similar results were obtained in three independent experiments and the IC50 is the mean ± SD of the three independent experiments. (B) Cell viability curves for ISM042-2-048 in cell line Huh7 and counter screen cell line HEK293. Data points are presented as the mean of duplicate wells in one experiment. Similar results were obtained in three independent experiments.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 59 references

Research works printed but not linked: 5

  1. Lin, 2021, Life, 11
  2. UniProt , UniProt Database , 2022 , https://www.uniprot.org/
  3. Science's 2021 Breakthrough of the Year: AI brings protein structures to all , https://www.science.org/content/article/breakthrough-2021 , 2022
  4. Zhavoronkov, 2022, Bioengineering
  5. M.Kuznetsov and D.Polykovskiy , Proceedings of the AAAI Conference on Artificial Intelligence , 2021 , vol. 35 , pp. 8226–8234

Cited by

Items 201–300 of 399

Metadata

Authors
Ren, F., Ding, X., Zheng, M., Korzinkin, M., Cai, X., Zhu, W., Mantsyzov, A., Aliper, A., Aladinskiy, V., Cao, Z., Kong, S., Long, X., Man Liu, B. H., Liu, Y., Naumov, V., Shneyderman, A., Ozerov, I. V., Wang, J., Pun, F. W., Polykovskiy, D. A., Sun, C., Levitt, M., Aspuru-Guzik, A., & Zhavoronkov, A.
Affiliations
  • Insilico Medicine Shanghai Ltd, Suite 901, Tower C, Changtai Plaza, 2889 Jinke Road. Pudong New District, Shanghai 201203, China
  • Insilico Medicine Kong Kong Ltd, Unit 310, 3/F, Building 8W, Phase 2, Hong Kong Science Park, Pak Shek Kok, Hong Kong, China
  • Canadian Institute for Advanced Research (CA)
  • Stanford University (US)
  • Department of Chemistry, Department of Computer Science, University of Toronto, Vector Institute for Artificial Intelligence, Canadian Institute for Advanced Research, Toronto, Ontario, Canada
Corresponding author
Zhavoronkov, Alex
Venue
Chemical Science
Published
2023
Volume
14
Issue
6
Pages
1443-1452
ISSN
  • 2041-6520 (ISSN-L)
  • 2041-6539
OpenAlex
W4313880353
Cited by
365
References
57
Citations by year
2026: 93 · 2025: 118 · 2024: 97 · 2023: 55
FWCI
51.96
Type
journal article
Language
en
Open access
Locations
  • Chemical Science (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
National Institute of General Medical Sciences (R35GM122543)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
Keywords
AlphaFold, small molecule inhibitors, hit identification, drug discovery, protein structure prediction, kinase inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.